Ovid Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

OVID$2.80-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)	September 30,2026	December 31,2025
Assets
Current assets:
Cash and cash equivalents	$13,811	$13,153
Marketable securities	122,790	56,482
Prepaid expenses and other current assets	5,357	4,733
Total current assets	141,958	74,368
Marketable securities - noncurrent	24,819	20,812
Long-term equity investments	42,694	41,961
Restricted cash	1,931	1,931
Right-of-use asset, net	10,656	11,610
Property and equipment, net	186	252
Total assets	$222,244	$150,934
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$5,856	$1,956
Accrued expenses	4,491	4,899
Current portion, lease liability	1,511	1,433
Total current liabilities	11,858	8,288
Long-term liabilities:
Lease liability	10,843	11,986
Royalty monetization liability	872	—
Total liabilities	23,573	20,274
Stockholders’ equity:
Common stock, $0.001 par value; 315,000,000 shares authorized; 188,720,929 and 130,184,353 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	189	130
Additional paid-in-capital	573,999	452,445
Accumulated other comprehensive loss	(1,027)	(202)
Accumulated deficit	(374,490)	(321,713)
Total stockholders’ equity	198,671	130,660
Total liabilities and stockholders’ equity	$222,244	$150,934

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.